In the News
NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
April 15, 2024
https://www.businesswire.com/news/home/20240415891824/en/NiKang-Therapeutics-Doses-First-Patient-in-a-Phase-11b-Study-of-NKT3447-an-Oral-Selective-Inhibitor-of-CDK2-Which-Reduces-Cyclin-E-Expression
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
April 5, 2024
https://www.businesswire.com/news/home/20240405485113/en/NiKang-Therapeutics-Presents-the-Discovery-and-Unique-Mechanism-of-Action-of-a-Selective-CDK2-Inhibitor-NKT3447-at-AACR-Annual-Meeting-2024
NiKang Therapeutics Appoints Joanne Lager,M.D., as Chief Medical Officer
January 4, 2024
https://www.businesswire.com/news/home/20240104711860/en/NiKang-Therapeutics-Appoints-Joanne-Lager-M.D.-as-Chief-Medical-Officer
NiKang Therapeutics Enters Into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
December 8, 2023
https://www.businesswire.com/news/home/20231208330578/en/NiKang-Therapeutics-Enters-into-Clinical-Trial-Collaboration-and-Supply-Agreement-to-Evaluate-NKT2152-in-Combination-with-Standard-of-Care-in-First-Line-Advanced-Hepatocellular-Carcinoma
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
January 18, 2023
https://www.businesswire.com/news/home/20230118005191/en/NiKang-Therapeutics-Appoints-Anne-E.-Borgman-M.D.-to-Board-of-Directors
NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China
May 3, 2022
https://www.businesswire.com/news/home/20220503005332/en/NiKang-Therapeutics-and-Hansoh-Pharma-Announce-Strategic-Collaboration-and-License-Agreement-for-NKT2152-in-Greater-China
NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022
April 8, 2022
https://www.businesswire.com/news/home/20220408005045/en/NiKang-Therapeutics-Presents-Preclinical-Data-Highlighting-NKT2152%E2%80%99s-Therapeutic-Potential-in-Clear-Cell-Renal-Cell-Carcinoma-ccRCC-and-Solid-Tumors-Beyond-ccRCC-at-AACR-Annual-Meeting-2022
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
November 30, 2021
https://www.businesswire.com/news/home/20211130005397/en/NiKang-Therapeutics-and-Pfizer-Enter-Clinical-Trial-Collaboration-and-Supply-Agreement-to-Evaluate-Novel-Combination-Therapies-for-the-Treatment-of-Advanced-Clear-Cell-Renal-Cell-Carcinoma
NiKang Therapeutics Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152, a Small Molecule that Inhibits Hypoxia Inducible Factor 2α (HIF2α), for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
November 15, 2021
https://www.businesswire.com/news/home/20211115005201/en/NiKang-Therapeutics-Announces-First-Patient-Dosed-in-A-Phase-12-Study-Evaluating-NKT2152-a-Small-Molecule-that-Inhibits-Hypoxia-Inducible-Factor-2%CE%B1-HIF2%CE%B1-for-the-Treatment-of-Advanced-Clear-Cell-Renal-Cell-Carcinoma
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
May 26, 2021
https://www.businesswire.com/news/home/20210526005183/en/NiKang-Therapeutics-Announces-Completion-of-200-Million-Series-C-Financing-to-Advance-Highly-Differentiated-Small-Molecules-Addressing-Difficult-to-Drug-Targets
NiKang Therapeutics Appoints Kelsey Chen, Ph.D., MBA, as Chief Financial Officer
April 5, 2021
https://www.einnews.com/pr_news/538003683/nikang-therapeutics-appoints-kelsey-chen-ph-d-mba-as-chief-financial-officer
Erasca announced the dosing of a first patient in December 2020 in Erasca’s FLAGSHP-1 study, a Phase 1/1b clinical trial to evaluate ERAS-601, a SHP2 inhibitor discovered and developed by NiKang Therapeutics
January 6, 2021
https://www.businesswire.com/news/home/20210106005241/en/Erasca-Unveils-Its-First-Strategy-to-Erase-Cancer-Accelerated-by-Expansion-of-Precision-Oncology-Pipeline-and-Dosing-of-First-Patient
NiKang Therapeutics Completes $50 Million Series B Financing
September 14, 2020
https://www.einnews.com/pr_news/526165507/nikang-therapeutics-completes-50-million-series-b-financing